Continuous venous infusion of vindesine in metastatic breast cancer: experience with a subcutaneously implanted system and portable pump.
Fourteen patients with advanced pretreated breast cancer were treated with vindesine in continuous venous infusion (1.5 mg/sm/24 hours for 72 hours every 3 weeks). A totally implanted venous access and a portable pump were used. A total of 33 courses was administered. No objective response was observed and treatment was stopped. Drug-related toxicity consisted mainly of alopecia (64% of patients), nausea and vomiting (29%) and mucositis (29%). Catheter - related toxicity was observed in 6 patients (43%) and consisted of infection of the skin pocket in 4 patients and dislodging of the needle and catheter break in one patient. The feasibility of continuous venous infusion of vesicant drugs in outpatients is discussed.
Amoroso
D
D
Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy.
Bertelli
G
G
Pronzato
P
P
Vidili
M G
MG
Gulisano
M
M
Lionetto
R
R
Rosso
R
R
D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007260:Infusion Pumps; D007262:Infusions, Intravenous; D008875:Middle Aged; D009362:Neoplasm Metastasis; D014751:Vindesine / Q000008:administration & dosage* / Q000009:adverse effects
D014751:Vindesine